rilzabrutinib + placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Autoimmune Haemolytic Anaemia
Conditions
Autoimmune Haemolytic Anaemia
Trial Timeline
Aug 18, 2025 → Dec 26, 2029
NCT ID
NCT07086976About rilzabrutinib + placebo
rilzabrutinib + placebo is a phase 3 stage product being developed by Sanofi for Autoimmune Haemolytic Anaemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07086976. Target conditions include Autoimmune Haemolytic Anaemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07086976 | Phase 3 | Recruiting |
| NCT06975865 | Phase 3 | Recruiting |
| NCT05104892 | Phase 2 | Completed |
| NCT05107115 | Phase 2 | Completed |
| NCT04562766 | Phase 3 | Active |
| NCT03762265 | Phase 3 | Terminated |
Competing Products
20 competing products in Autoimmune Haemolytic Anaemia